Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force 
WATERTOWN, Mass., March 06, 2017 -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will give a corporate presentation at the 29th Annual ROTH Conference on Monday, March 13, 2017 at 8:00 a.m. Pacific Time at the Ritz Carlton Hotel in Dana Point, CA.
A live audio webcast of the ROTH presentation will be available on the company’s website at http://ir.tphase.com/events.cfm. An archived presentation will be available for 30 days.
About Tetraphase Pharmaceuticals, Inc.
Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections, including those caused by many of the multidrug-resistant (MDR) bacteria highlighted as urgent public health threats by the CDC. Tetraphase has created more than 3,000 novel tetracycline analogs using its proprietary technology platform. Tetraphase's pipeline includes three antibiotic clinical candidates: eravacycline, which is in phase 3 clinical trials, and TP-271 and TP-6076, which are in phase 1 clinical trials. Please visit www.tphase.com for more company information.
Investor Contacts: Tetraphase Pharmaceuticals Teri Dahlman 617-600-7040 [email protected] Argot Partners Maeve Conneighton 206-899-4940 [email protected] Media Contact: Sam Brown Inc. Mike Beyer 312-961-2502 [email protected]
